Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (131-140 of 272) with videos related to

Pageof 28
Sort By:
Kidney360|December 26, 2024
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial ResultsHong Zhang, Richard Lafayette, Bei Wang, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in JapanTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney International Reports|November 9, 2020
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA NephropathyRichard A Lafayette, Brad H Rovin, Heather N Reich, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 29, 2024
Enhancing collaboration between academia and industry in kidney disease researchRobert J Unwin, Benjamin Challis, Iain MacPhee, et al.
Advances in Therapy|February 7, 2023
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 StudiesJonathan Barratt, Frank Dellanna, Jose Portoles, et al.
Kidney International Reports|May 16, 2022
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG<sub>2</sub> Monoclonal Antibody, in Healthy VolunteersMohit Mathur, Jonathan Barratt, Yusuke Suzuki, et al.
Kidney International|July 29, 2017
β1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cellsKaren Molyneux, David Wimbury, Izabella Pawluczyk, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 15, 2025
Urinary carbonic anhydrase 1 as a marker of hematuria in IgA nephropathyTomas G J M Post, Nils Rother, Elmar Pieterse, et al.
Kidney International Reports|October 26, 2020
Why Target the Gut to Treat IgA Nephropathy?Jonathan Barratt, Brad H Rovin, Daniel Cattran, et al.
Clinical and Experimental Medicine|June 23, 2009
Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndromeJacob F de Wolff, Stephen J Dickinson, Alice C Smith, et al.
Pageof 28

Showing results (131-140 of 272) with videos related to

Sort By:
Pageof 28
Kidney360|December 26, 2024
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial ResultsHong Zhang, Richard Lafayette, Bei Wang, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in JapanTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney International Reports|November 9, 2020
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA NephropathyRichard A Lafayette, Brad H Rovin, Heather N Reich, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 29, 2024
Enhancing collaboration between academia and industry in kidney disease researchRobert J Unwin, Benjamin Challis, Iain MacPhee, et al.
Advances in Therapy|February 7, 2023
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 StudiesJonathan Barratt, Frank Dellanna, Jose Portoles, et al.
Kidney International Reports|May 16, 2022
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG<sub>2</sub> Monoclonal Antibody, in Healthy VolunteersMohit Mathur, Jonathan Barratt, Yusuke Suzuki, et al.
Kidney International|July 29, 2017
β1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cellsKaren Molyneux, David Wimbury, Izabella Pawluczyk, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 15, 2025
Urinary carbonic anhydrase 1 as a marker of hematuria in IgA nephropathyTomas G J M Post, Nils Rother, Elmar Pieterse, et al.
Kidney International Reports|October 26, 2020
Why Target the Gut to Treat IgA Nephropathy?Jonathan Barratt, Brad H Rovin, Daniel Cattran, et al.
Clinical and Experimental Medicine|June 23, 2009
Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndromeJacob F de Wolff, Stephen J Dickinson, Alice C Smith, et al.
Pageof 28